| Maronan Metals Limited (MMA) ORDINARY FULLY PAID |
Materials |
$118 |
Half Yearly Report and Accounts
|
24 Feb 2025 8:12AM |
$0.295 |
$0.470 |
risen by
59.32%
|
|
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,196 |
FY25 half year results announcement
|
24 Feb 2025 8:12AM |
$5.940 |
$6.550 |
risen by
10.27%
|
|
NHF - Price-sensitive ASX Announcement
Full Release
Key Points
- Total Group revenue $1.8 billion, up 7.7% from $1.7 billion in 1H24
- Group underlying operating profit (UOP) $105.8 million, down from $144.3 million 1H24
- Australian residents’ policyholder growth at 3.3%
- Net profit after tax $82.9 million from $103.9 million 1H24
- Statutory earnings per share cents 17.1 from 22.0 cps 1H24
- Interim fully franked dividend of 13 cents per share, fully franked (1H24:15 cps)
- Claims inflation eased from 5.9% to 5.0% between reporting periods
- nib's international students and workers health insurance business grew solidly
- nib NZ showed signs of recovery with profitable months in December and January
- Group Operating Expense Ratio reduced from 17.9% in 1H24 to 17.5% in 1H25
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,196 |
Dividend/Distribution - NHF
|
24 Feb 2025 8:12AM |
$5.940 |
$6.550 |
risen by
10.27%
|
|
| NIB Holdings Limited (NHF) ORDINARY FULLY PAID |
Financials |
$3,196 |
Appendix 4D and 2024 Interim Report
|
24 Feb 2025 8:11AM |
$5.940 |
$6.550 |
risen by
10.27%
|
|
NHF - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 8% to $1.837 billion.
- Net profit attributable to members decreased by 22% to $82.9 million.
- Interim dividend reduced from 15 cents to 13 cents per share.
- Challenges in claims inflation affecting the health insurance sector.
- Integration costs from recent acquisitions impacted overall profitability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oohmedia Limited (OML) ORDINARY FULLY PAID |
Communication Services |
$585 |
Appendix 4E and Full Year Financial Report
|
24 Feb 2025 8:11AM |
$1.285 |
$1.085 |
fallen by
15.56%
|
|
OML - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 0.3% to $635.6 million in CY24.
- Adjusted gross profit rose by 1% to $284.4 million.
- Profit attributable to members increased by 5.7% to $36.6 million.
- Final dividend declared at 3.50 cents per share.
- Strategic initiatives helped drive revenue growth in the second half of the year.
- Restructuring planned to simplify operations and reduce costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brazilian Critical Minerals Limited (BCM) ORDINARY FULLY PAID |
Materials |
$70 |
Investor Webinar
|
24 Feb 2025 8:10AM |
$0.010 |
$0.036 |
risen by
260%
|
|
| Veris Limited (VRS) ORDINARY FULLY PAID |
Industrials |
$36 |
Veris Ltd - FY25 Half Year Results Presentation
|
24 Feb 2025 8:09AM |
$0.047 |
$0.067 |
risen by
42.55%
|
|
VRS - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic Acquisition: Acquisition of Spatial Vision to bolster digital solutions and advisory service offering.
- Rebound in Profitability: PBT of $1.0m, up 212% from PCP.
- Margin Improvement: PBT margin increased to 2.1%, up 200% from PCP.
- Strategic Revenue Focus: Revenue of $46.8m, aligning with strategic focus on higher-margin project selection.
- Digital Expansion: Share of revenue from digital and spatial data consulting services increase to 20.4%.
- Strong Cash Position and Order Book: Cash balance rose to $17.6m, with a secured forward workload over $55m.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Veris Limited (VRS) ORDINARY FULLY PAID |
Industrials |
$36 |
FY25 Half Year Results Announcement
|
24 Feb 2025 8:09AM |
$0.047 |
$0.067 |
risen by
42.55%
|
|
VRS - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit Before Tax (PBT) of $1.0m up 212% on the prior corresponding period.
- PBT margin improved significantly to 2.1%, up 200% from the equivalent pcp.
- Unaudited revenue of $46.8m was down 3.3% on the pcp, consistent with Veris’ strategy.
- Veris' cash balance rose to $17.6 million as of 31 December 2024.
- Financial improvements in H1 FY25 highlight the successful execution of Veris' transformation strategy.
- Acquisition of Spatial Vision to bolster Veris’ existing digital solutions and advisory service offerings.
- Secured forward workload exceeds $55 million as at end-H1 FY25.
- Unsecured project pipeline remains robust with a weighted value of more than $190 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nuix Limited (NXL) ORDINARY FULLY PAID |
Information Technology |
$461 |
1H25 Financial Results Investor Presentation
|
24 Feb 2025 8:09AM |
$4.780 |
$1.378 |
fallen by
71.18%
|
|
NXL - Price-sensitive ASX Announcement
Full Release
Key Points
- ACV increased by 8.3% to $216.2 million
- Total revenue rose by 6.9% to $105.2 million
- Cash EBITDA grew by 30.6% to $13.4 million
- Nuix Neo platform expanded to 46 customers
- Underlying cash flow positive
- Strategic targets for FY25 include 11% - 16% ACV growth
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nuix Limited (NXL) ORDINARY FULLY PAID |
Information Technology |
$461 |
1H25 Results
|
24 Feb 2025 8:08AM |
$4.780 |
$1.378 |
fallen by
71.18%
|
|
NXL - Price-sensitive ASX Announcement
Full Release
Key Points
- ACV growth of 8.3% to $216.2 million
- Cash EBITDA increased by 30.6% to $13.4 million
- Positive underlying cash flow of $7.0 million
- Nuix Neo ACV growth to $18.9 million, up 361%
- Net loss after tax of $10.4 million
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Veris Limited (VRS) ORDINARY FULLY PAID |
Industrials |
$36 |
Veris Ltd - FY25 Half Year Accounts
|
24 Feb 2025 8:08AM |
$0.047 |
$0.067 |
risen by
42.55%
|
|
| Veris Limited (VRS) ORDINARY FULLY PAID |
Industrials |
$36 |
FY25 H1 Appendix 4D
|
24 Feb 2025 8:08AM |
$0.047 |
$0.067 |
risen by
42.55%
|
|
VRS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 3% to $46,755,000.
- EBIT increased by 117% to $1,238,000.
- Profit before tax increased by 212% to $998,000.
- Profit margin improved from 0.7% to 2.1%.
- Earnings per share rose from 0.06 cents to 0.20 cents.
- No dividends declared during the reporting period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Liberty Financial Group (LFG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Financials |
$1,178 |
LFG Half Year Results - Presentation
|
24 Feb 2025 8:08AM |
$3.820 |
$3.880 |
risen by
1.57%
|
|
| Liberty Financial Group (LFG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Financials |
$1,178 |
LFG Half Year Results - Media Release
|
24 Feb 2025 8:08AM |
$3.820 |
$3.880 |
risen by
1.57%
|
|
| Nuix Limited (NXL) ORDINARY FULLY PAID |
Information Technology |
$461 |
Half Yearly Report and Accounts
|
24 Feb 2025 8:08AM |
$4.780 |
$1.378 |
fallen by
71.18%
|
|
NXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Announcement date is 24 February 2025.
- Nuix Limited reported a 6.9% increase in revenue to AUD 105.19 million.
- The company faced a loss after tax of AUD 10.4 million.
- Legal fees related to litigation were significant during this period.
- The proportion of revenue from multi-year deals decreased.
- Nuix Neo sales saw a strong growth with more new customers.
- No dividends were declared for the half-year.
- Nuix is currently involved in ongoing legal proceedings including ASIC and class action lawsuits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Liberty Financial Group (LFG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Financials |
$1,178 |
LFG Half Year Results - Announcement
|
24 Feb 2025 8:08AM |
$3.820 |
$3.880 |
risen by
1.57%
|
|
| Liberty Financial Group (LFG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Financials |
$1,178 |
LFG Appendix 4D and FY25 Half Year Interim Report
|
24 Feb 2025 8:07AM |
$3.820 |
$3.880 |
risen by
1.57%
|
|
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$64 |
Vection Wins $0.6m SaaS Deal in France
|
24 Feb 2025 8:07AM |
$0.027 |
$0.029 |
risen by
5.56%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Vection wins $0.6M SaaS deal in France with Augmentalix.
- The agreement spans three years and focuses on AI and XR software solutions.
- Sales milestones are set at $165k for 2025, $165k for 2026, and $250k for 2027.
- The partnership expands Vection's presence in Central Europe.
- Augmentalix will actively market and distribute Vection’s portfolio in France.
- This collaboration signifies growing market confidence in Vection’s solutions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$127 |
Paradigm Secures Ethics Approval for Phase 3 Trial
|
24 Feb 2025 8:06AM |
$0.615 |
$0.290 |
fallen by
52.85%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Ethics approval received from Australia's centralised Human Research Ethics Committee for the PARA_OA_012 Phase 3 trial.
- The trial evaluates injectable pentosan polysulphate sodium (iPPS) for knee osteoarthritis treatment.
- First participant dosing anticipated in Q2 CY2025.
- Recruitment activities to commence following site activations across up to 10 sites in Australia.
- Paradigm is focused on adhering to projected timelines for the Phase 3 study.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lovisa Holdings Limited (LOV) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,950 |
1H FY25 Half Year Results Presentation
|
24 Feb 2025 8:06AM |
$29.300 |
$26.640 |
fallen by
9.08%
|
|
LOV - Price-sensitive ASX Announcement
Full Release
Key Points
- Total sales up 8.8% on prior half year
- Global comparable store sales for the period up 0.1%
- Gross Margin up 170bps to 82.4%
- EBIT up 10.7% to $90.2m
- NPAT up 6.5% to $56.9m
- 943 stores at the end of the period
- 57 new stores opened for the period
- Interim dividend of 50 cents, unfranked
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SelfWealth Limited (SWF) ORDINARY FULLY PAID |
Financials |
- |
Selfwealth receives binding proposal from Svava
|
24 Feb 2025 8:06AM |
$0.280 |
$0.278 |
fallen by
0.89%
|
|
SWF - Price-sensitive ASX Announcement
Full Release
Key Points
- Selfwealth received a binding proposal from Svava Pte Ltd.
- The offer is for $0.28 cash per share, a 12% premium to Bell's offer.
- Svava holds approximately 18.8% of Selfwealth shares.
- Selfwealth initiated a matching rights process with Bell Financial Group.
- Bell must respond to the proposal by 26 February 2025.
- Shareholders do not need to take action at this time.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bell Financial Group Limited (BFG) ORDINARY FULLY PAID |
Financials |
$475 |
SWF: Selfwealth receives binding proposal from Svava
|
24 Feb 2025 8:06AM |
$1.360 |
$1.480 |
risen by
8.82%
|
|
BFG - Price-sensitive ASX Announcement
Full Release
Key Points
- Selfwealth receives binding proposal from Svava.
- Svava offers $0.28 cash per share for acquisition.
- This represents a 12% premium over Bell's offer of $0.25 per share.
- Svava owns approximately 18.8% of Selfwealth shares.
- Selfwealth Board has started the matching rights process.
- Bell has until 26 February 2025 to respond with a counterproposal.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Australia Bank Limited (NAB) ORDINARY FULLY PAID |
Financials |
$147,364 |
Update - Notification of buy-back - NAB
|
24 Feb 2025 8:06AM |
$35.080 |
$48.040 |
risen by
36.94%
|
|
| Lovisa Holdings Limited (LOV) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,950 |
1H FY25 Half Year Results Announcement
|
24 Feb 2025 8:06AM |
$29.300 |
$26.640 |
fallen by
9.08%
|
|
LOV - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue up 8.8% to $405.9m
- Net Profit After Tax up 6.5% to $56.9m
- Gross Margin improved to 82.4%
- 57 new stores opened, total 943 stores
- Operating cash flow of $141.1m
- Interim Dividend of 50.0 cents per share
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Memphasys Limited (MEM) ORDINARY FULLY PAID |
Health Care |
$19 |
Felix Data lock complete and regulatory submission commenced
|
24 Feb 2025 8:06AM |
$0.006 |
$0.007 |
risen by
8.33%
|
|
MEM - Price-sensitive ASX Announcement
Full Release
Key Points
- Data lock completed for the pivotal Felix™ clinical trial.
- Data is ready for statistical analysis after final quality checks.
- Preliminary trial results are on track for release in March 2025.
- CE Mark submission is planned for June 2025.
- Market entry into Europe, Australia, and India is planned post CE Mark approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
